Turn Therapeutics (TTRX) Cash & Equivalents (2024 - 2026)

Turn Therapeutics' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $11.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (changed N/A YoY), while the FY2025 annual figure was $4.0 million, up 708.34% from the prior year.
• Cash & Equivalents was $11.0 million for Q1 2026 at Turn Therapeutics, up from $4.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $11.0 million in Q1 2026 to a low of $498286.0 in Q3 2024.
• Historically, Cash & Equivalents has averaged $3.3 million across 3 years, with a median of $513695.0 in 2025.
• Biggest YoY gain for Cash & Equivalents was 708.34% in 2025; the steepest drop was 3.09% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $498286.0 in 2024, then soared by 708.34% to $4.0 million in 2025, then surged by 173.33% to $11.0 million in 2026.
• The last three Cash & Equivalents figures came in at $11.0 million (Q1 2026), $4.0 million (Q4 2025), and $513695.0 (Q3 2025), per Business Quant data.